Akari Therapeutics PLC (AKTX) vs Neuphoria Therapeutics Inc. (NEUP)

Akari Therapeutics PLC and Neuphoria Therapeutics Inc. are both Biotechnology companies. Neuphoria Therapeutics Inc. is the larger, with a market value of $19.8M against $17.6M — 1.1× the size. Across the 10 metrics below, Neuphoria Therapeutics Inc. leads on 6 and Akari Therapeutics PLC on 4.

Valuation

Metric AKTX NEUP Biotechnology median
P/E n/m n/m 7.88
P/S n/m 1.02 11.47
P/B 0.94 0.65 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.17 0.74
EV/Sales n/m (0.19) 10.73
Earnings yield (265.10%) (138.08%) (28.84%)
Free cash flow yield (61.74%) (76.04%) (23.03%)

Profitability

Metric AKTX NEUP Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (140.09%) (61.70%) (57.72%)
Return on assets (69.16%) (46.95%) (49.22%)
Return on invested capital (167.93%) (232.67%) 0.00%

Growth

Metric AKTX NEUP Biotechnology median
Revenue growth (TTM) — 3,535.05% 5.64%
EPS growth (last fiscal year) 68.99% (1,230.43%) —
Revenue growth, 5-year CAGR — 19.07% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX NEUP Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 0.60 27.85 4.73
Net debt to EBITDA 0.27 1.26 0.96

Dividend

Metric AKTX NEUP Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AKTX NEUP Biotechnology median
Market cap 17.61m 19.75m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack